1-4 of 4
Angimar Uriepero
Close
Sort by
Journal Articles

Targeting Inflammatory Pathways to Reverse Immunosuppressive Tumor Microenvironment in Chronic Lymphocytic Leukemia

Angimar Uriepero, Melanie Mediavilla-Varela, Kamira Maharaj, Wael Gamal, Maria Elena Marquez, John J. Powers, Vishaal Kunta, Eva Sahakian, Pablo Oppezzo, Javier Pinilla Ibarz
Journal: Blood
Blood (2022) 140 (Supplement 1): 6988–6989.
https://doi.org/10.1182/blood-2022-167331
Published: 2022
Journal Articles

Metabolic Abnormalities Associated with T-Cell Exhaustion in CLL Eµ-TCL1 Murine Model

Wael Gamal, Melanie Mediavilla-Varela, Kamira Maharaj, Angimar Uriepero, Vishaal Kunta, Eva Sahakian, Javier Pinilla Ibarz
Journal: Blood
Blood (2022) 140 (Supplement 1): 6994–6995.
https://doi.org/10.1182/blood-2022-166704
Published: 2022
Journal Articles

Efficacy of Vecabrutinib Treatment in a Murine Model of Sclerodermatous Graft-Versus-Host-Disease

Kamira Maharaj, Melanie Mediavilla-Varela, Angimar Uriepero, Judith A. Fox, Pietro Taverna, Wael Gamal, Eva Sahakian, Javier Pinilla Ibarz
Journal: Blood
Blood (2021) 138 (Supplement 1): 1685.
https://doi.org/10.1182/blood-2021-150598
Published: 2021
Journal Articles

Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia

Pablo Elías Morande, Mariela Sivina, Angimar Uriepero, Noé Seija, Catalina Berca, Pablo Fresia, Ana Inés Landoni, Javier M. Di Noia, Jan A. Burger, Pablo Oppezzo
Journal: Blood
Blood (2019) 133 (19): 2056–2068.
https://doi.org/10.1182/blood-2018-09-876292
Published: 2019
Includes: Supplemental data